279 related articles for article (PubMed ID: 22363068)
1. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
Oncologist; 2012; 17(3):321. PubMed ID: 22363068
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
Qi WX; He AN; Tang LN; Shen Z; Lin F; Yao Y
Jpn J Clin Oncol; 2012 May; 42(5):427-31. PubMed ID: 22450929
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation.
Oesterheld JE; Reed DR; Setty BA; Isakoff MS; Thompson P; Yin H; Hayashi M; Loeb DM; Smith T; Makanji R; Fridley BL; Wagner LM
Pediatr Blood Cancer; 2020 Jul; 67(7):e28370. PubMed ID: 32386107
[TBL] [Abstract][Full Text] [Related]
4. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
Navid F; Willert JR; McCarville MB; Furman W; Watkins A; Roberts W; Daw NC
Cancer; 2008 Jul; 113(2):419-25. PubMed ID: 18484657
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.
Palmerini E; Jones RL; Marchesi E; Paioli A; Cesari M; Longhi A; Meazza C; Coccoli L; Fagioli F; Asaftei S; Grignani G; Tamburini A; Pollack SM; Picci P; Ferrari S
BMC Cancer; 2016 Apr; 16():280. PubMed ID: 27098543
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
Mora J; Cruz CO; Parareda A; de Torres C
J Pediatr Hematol Oncol; 2009 Oct; 31(10):723-9. PubMed ID: 19727011
[TBL] [Abstract][Full Text] [Related]
9. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
Leu KM; Ostruszka LJ; Shewach D; Zalupski M; Sondak V; Biermann JS; Lee JS; Couwlier C; Palazzolo K; Baker LH
J Clin Oncol; 2004 May; 22(9):1706-12. PubMed ID: 15117993
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Lee EM; Rha SY; Lee J; Park KH; Ahn JH
Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
[TBL] [Abstract][Full Text] [Related]
11. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
Mora J; Castañeda A; Perez-Jaume S; Lopez-Pousa A; Maradiegue E; Valverde C; Martin-Broto J; Garcia Del Muro X; Cruz O; Cruz J; Martinez-Trufero J; Maurel J; Vaz MA; de Alava E; de Torres C
Br J Cancer; 2017 Sep; 117(6):767-774. PubMed ID: 28787430
[TBL] [Abstract][Full Text] [Related]
12. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
[TBL] [Abstract][Full Text] [Related]
14. Real-world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study.
Peretz Soroka H; Vora T; Noujaim J; Marcoux N; Cohen-Gogo S; Alcindor T; Holloway C; Rodrigues C; Karachiwala H; Alvi S; Lee U; Cheng S; Banerji S; Oberoi S; Feng X; Smrke A; Simmons C; Razak AA; Gupta AA
Cancer Med; 2023 Sep; 12(18):18872-18881. PubMed ID: 37724607
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Tansir G; Rastogi S; Kumar A; Barwad A; Mridha AR; Dhamija E; Shamim SA; Bhatnagar S; Bhoriwal S
BMC Cancer; 2023 Jul; 23(1):639. PubMed ID: 37422615
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
He A; Qi W; Huang Y; Sun Y; Shen Z; Zhao H; Yang Y; Yao Y
Int J Clin Oncol; 2013 Jun; 18(3):498-505. PubMed ID: 22534798
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital.
Gosiengfiao Y; Reichek J; Woodman J; Ben-Ami T; Walterhouse D
J Pediatr Hematol Oncol; 2012 Mar; 34(2):e63-5. PubMed ID: 22217487
[TBL] [Abstract][Full Text] [Related]
18. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer.
Albertsson M; Johansson B; Friesland S; Kadar L; Letocha H; Frykholm G; Wagenius G
Med Oncol; 2007; 24(4):407-12. PubMed ID: 17917090
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
Merimsky O; Meller I; Flusser G; Kollender Y; Issakov J; Weil-Ben-Arush M; Fenig E; Neuman G; Sapir D; Ariad S; Inbar M
Cancer Chemother Pharmacol; 2000; 45(2):177-81. PubMed ID: 10663634
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma.
Lee JA; Paik EK; Seo J; Kim DH; Lim JS; Yoo JY; Kim MS
Jpn J Clin Oncol; 2016 Feb; 46(2):138-43. PubMed ID: 26685322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
